8-K: OptimizeRx Announces Finance Leadership Changes, Q2 Results

OptimizeRx reported a 30% year-over-year revenue decrease for Q2 2026, alongside a net loss, while reaffirming full-year guidance and announcing key finance leadership appointments.

Summary

• OptimizeRx announced its financial results for the second quarter ended June 30, 2026, and a finance leadership succession plan.
• Q2 2026 revenue was $20.5 million, a 30% decrease from $29.2 million in Q2 2025.
• The company reported a GAAP net loss of $(0.7) million for Q2 2026, compared to a net income of $1.5 million in Q2 2025.
• Adjusted EBITDA for Q2 2026 was $4.9 million, down from $5.8 million in Q2 2025.
• The company is reaffirming its full-year 2026 guidance for revenue ($95 $100 million) and adjusted EBITDA ($21 $25 million).
• Edward Stelmakh will step down as Chief Financial & Strategy Officer on December 31, 2026.
• Andrew DSilva will become Chief Financial Officer and Heather Favazza will become Chief Accounting Officer, both effective January 1, 2027.
• Mr. Stelmakh will provide advisory services for 12 months and will receive a severance package including salary continuation, bonus, and COBRA reimbursement.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed sentiment. While leadership transitions are planned, the Q2 financial results show a significant year-over-year revenue decline and a net loss, although adjusted EBITDA and revenue exceeded consensus expectations. The company reaffirms full-year guidance, but the revenue contraction is a concern.

Positives

• Second quarter revenue and adjusted EBITDA exceeded consensus expectations.
• Continued margin expansion and disciplined execution noted.
• Reaffirmed full-year 2026 revenue guidance of $95 million to $100 million.
• Reaffirmed full-year 2026 adjusted EBITDA guidance of $21 million to $25 million.
• Completed debt refinancing with a $35 million banking facility.
• Repaid $8.3 million of debt principal since inception, with $5.3 million paid in Q2 2026.
• Strengthened balance sheet with $24.1 million in cash and cash equivalents as of June 30, 2026.
• Launched three platform advancements: DeepIntent integration, Natural Language Audience Builder, and CopayCue.

Negatives

• Revenue decreased 30% to $20.5 million in Q2 2026 compared to $29.2 million in Q2 2025.
• Reported a GAAP net loss of $(0.7) million in Q2 2026, compared to a net income of $1.5 million in Q2 2025.
• Non-GAAP net income decreased to $3.1 million in Q2 2026 from $3.7 million in Q2 2025.
• Adjusted EBITDA decreased to $4.9 million in Q2 2026 from $5.8 million in Q2 2025.
• Net revenue retention was 90% in Q2 2026, down from 121% in Q2 2025.
• The year-over-year revenue decline and contracted revenue are concentrated among a small number of customers.

Risks

• Dependence on a concentrated group of customers.
• Cybersecurity incidents that could disrupt operations.
• The ability to keep pace with growing and evolving technology.
• The ability to maintain contracts with electronic prescription platforms and electronic health records networks.
• Competition in the healthcare technology sector.
• Government regulation impacting the business.
• Seasonal trends affecting performance.
• Potential for future variability in second-half timing and mix.

Future Outlook

The company is reaffirming its fiscal year 2026 guidance for revenue between $95 million and $100 million, and adjusted EBITDA between $21 million and $25 million. Management expresses confidence in the full-year outlook based on first-half performance and commercial momentum, despite some variability in second-half timing and mix.

Management Comments

• "Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and resilience in our operating model."
• "While year-over-year revenue declined and contracted revenue remains below prior-year levels, these trends are concentrated among a small number of customers, and we are encouraged by increased investment across other portions of our customer base."
• "Our continued investment in platform capabilities, including recent product launches and expanded programmatic initiatives, is strengthening customer engagement as we move into the 2027 planning cycle."
• "Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in revenue and $21 million to $25 million in adjusted EBITDA."
• "Ed has been an exceptional partner to me, our Board, and our executive leadership team. His guidance has strengthened our financial foundation, sharpened our strategic execution, and helped build an outstanding finance organization. Perhaps his most enduring contribution is the talented team he has developed, which gives us confidence in this leadership change."
• "Andy has most recently served as Chief Business Officer and has worked closely with the executive leadership team and the Board on the Companys financial strategy, capital allocation, investor relations, corporate development, and long-range planning. His work has been vital to the strong financial foundation we have established, which makes him well-positioned to step into this new role."
• "Heather has been the Companys Corporate Controller for the past eight years and has consistently demonstrated strong leadership, technical expertise, and an unwavering commitment to excellence. She has been instrumental in strengthening accounting operations, financial reporting, internal controls, compliance, and the Companys finance infrastructure and is well prepared to serve as our Chief Accounting Officer."

Industry Context

StockSavvy.ai notes that OptimizeRx operates in the healthcare technology sector, a space focused on leveraging data and technology to improve engagement between life sciences companies, healthcare professionals, and patients. The company's focus on AI-enabled audience intelligence and programmatic point-of-care activation aligns with broader industry trends towards more personalized and efficient healthcare marketing. The reported revenue decline, while concerning, may reflect broader market dynamics or customer-specific issues within this specialized niche.

Management Changes

Stakeholder Impact

• Shareholders: The reaffirmation of full-year guidance and leadership succession plan may provide some stability, but the revenue decline and net loss could be viewed negatively. The company aims to create long-term shareholder value.
• Employees: The finance leadership transition is part of a succession plan, indicating internal development and stability within the finance department. Severance packages are outlined for departing executives.
• Customers: The company highlights increased investment from a portion of its customer base and platform advancements, suggesting continued engagement and value proposition.
• Creditors: The company completed a debt refinancing and repaid principal, strengthening its financial position.

Next Steps

• Edward Stelmakh will continue as Chief Financial & Strategy Officer through December 31, 2026, working with his successors.
• Edward Stelmakh will provide advisory services to the Company for 12 months following his departure.
• Andrew DSilva and Heather Favazza will assume their new roles on January 1, 2027.
• The company will continue to invest in platform capabilities and programmatic initiatives.
• Management will host a conference call on August 12, 2026, to discuss Q2 results and outlook.
• OptimizeRx management will host individual meetings with institutional investors.

Key Dates

Recommendation

The company is navigating a challenging revenue environment with a significant year-over-year decline, despite exceeding some expectations and reaffirming guidance. The planned leadership transition is positive for succession, but the underlying financial performance warrants caution. A 'hold' recommendation reflects the balance between the company's strategic initiatives and its current financial headwinds.

Keywords

healthcare technology, life sciences, financial results, leadership transition, EHR, HCP engagement, adjusted EBITDA, revenue guidance